YKL-40 and mesothelin in the blood of patients with malignant mesothelioma, lung cancer and asbestosis

Anticancer Research

Volumn 33, Issue 12, 2013, Pages 5517-5524

  Corradi, Massimo ^a   Goldoni, Matteo ^a   Alinovi, Rossella ^a   Tiseo, Marcello ^b   Ampollini, Luca ^b   Bonini, Silvia ^a   Carbognani, Paolo ^b   Casalini, Angelo ^b   Mutti, Antonio ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

Lung cancer; Malignant mesothelioma; Mesothelin; YKL 40

Indexed keywords

ASBESTOS; BIOLOGICAL MARKER; CARRIER PROTEINS AND BINDING PROTEINS; CHITINASE 3 LIKE PROTEIN 1; ENDOTHELIN 1; FIBULIN 3; INTERLEUKIN 8; MESOTHELIN; PROTEIN; SCLEROPROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASBESTOSIS; CANCER DIAGNOSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; MIDDLE AGED; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; VENOUS BLOOD;

EID: 84891458415     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Chapman A, Mulrennan S, Ladd B and Muers MF: Population based epidemiology and prognosis of mesothelioma in Leeds, UK. Thorax 63: 435-439, 2008.
2. Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, DeCamp MM Jr., Swanson SJ, Bueno R, Lukanich JM, Baldini EH and Mentzer SJ: Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients. J Thorac Cardiovasc Surg 117: 54-63, 1999.
3. Fasola G, Belvedere O, Aita M, Zanin T, Follador A, Cassetti P, Meduri S, De Pangher V, Pignata G, Rosolen V, Barbone F and Grossi F: Low-dose computed tomography screening for lung cancer and pleural mesothelioma in an asbestos-exposed population: baseline results of a prospective, nonrandomized feasibility trial - an Alpe-adria Thoracic Oncology Multidisciplinary Group Study (ATOM 002). Oncologist 12: 1215-1224, 2007.
4. Astoul P, Roca E, Galateau-Salle F and Scherpereel A: Malignant pleural mesothelioma: from the bench to the bedside. Respiration 83: 481-493, 2012.
5. Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, Carbone M and Allard J: Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg 85: 265-272, 2008.
6. Hollevoet K, Reitsma JB, Creaney J, Grigoriu BD, Robinson BW, Scherpereel A, Cristaudo A, Pass HI, Nackaerts K, Rodríguez Portal JA, Schneider J, Muley T, Di Serio F, Baas P, Tomasetti M, Rai AJ and van Meerbeeck JP: Serum mesothelin for diagnosing malignant pleural mesothelioma: An individual patient data meta-analysis. J Clin Oncol 30: 1541-1549, 2012.
7. Creaney J, Yeoman D, Musk AW, de Klerk N, Skates SJ and Robinson BW: Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma - Which is best? Lung Cancer 74: 55-60, 2011.
8. Suzuki H, Hirashima T, Kobayashi M, Sasada S, Okamoto N, Uehara N, Tamiya M, Matsuura Y, Morishita N and Kawase I: Cytokeratin 19 fragment/ carcinoembryonic antigen ratio in pleural effusion is a useful marker for detecting malignant pleural mesothelioma. Anticancer Res 30: 4343-4346, 2010.
9. Grigoriu BD, Grigoriu C, Chahine B, Gey T and Scherpereel A: Clinical utility of diagnostic markers for malignant pleural mesothelioma. Monaldi Arch Chest Dis 71: 31-38, 2009.
10. Junker N, Johansen JS, Andersen CB and Kristjansen PE: Expression of YKL-40 by peritumoral macrophages in human small cell lung cancer. Lung cancer 48: 223-231, 2005.
11. Johansen JS, Bojesen SE, Mylin AK, Frikke-Schmidt R, Price PA and Nordestgaard BG. Elevated plasma YKL-40 predicts increased risk of gastrointestinal cancer and decreased survival after any cancer diagnosis in the general population. J Clin Oncol 27: 572-578, 2009.
12. Kim HR, Jun CD, Lee KS, Cho JH, Jeong ET, Yang SH, Lee YJ and Park DS: Levels of YKL-40 in pleural effusion and blood from patients with pulmonary or pleural disease. Cytokine 58: 336-343, 2012.
13. Thöm I, Andritzky B, Schuch G, Burkholder I, Edler L, Johansen JS, Bokemeyer C, Schumacher U and Laack E: Elevated pretreatment serum concentration of YKL-40 - An independent prognostic biomarker for pool survival in patients with metatstatic nonsmall cell lung cancer. Cancer 116: 4114-4121, 2010.
14. Arun C, DeCatris M, Hemingway DM, London NJ and O'Byrne KJ. Endothelin-1 is a novel prognostic factor in non-small cell lung cancer. Int J Biol Markers 19: 262-267, 2004.
15. Fujimoto N, Gemba K and Kishimoto T: Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma. J Thorac Oncol 6: 971-972, 2011.
16. Galffy G, Mohammed KA, Dowling PA, Nasreen N, Ward MJ and Antony VB: Interleukin 8: An autocrine growth factor for malignant mesothelioma. Cancer Res 59: 367-371, 1999.
17. Pass HI, Levin SM, Harbut MR, Melamed J, Chiriboga L, Donington J, Huflejt M, Carbone M, Chia D, Goodglick L, Goodman GE, Thornquist MD, Liu G, de Perrot M, Tsao MS and Goparaju C: Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med 367: 1417-1427, 2012.
18. Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, de Vuyst P, Dienemann H, Galateau-Salle F, Hennequin C, Hillerdal G, Le P'choux C, Mutti L, Pairon JC, Stahel R, van Houtte P, van Meerbeeck J, Waller D, Weder W and European Respiratory Society/European Society of Thoracic Surgeons Task Force. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 35: 479-495, 2010.
19. Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG and Shepherd FA: Non-small cell lung cancer. Lancet 378: 1727-1740, 2011.
20. van den Heuvel MM, Korse CM, Bonfrer JM and Baas P: Noninvasive diagnosis of pleural malignancies: The role of tumour markers. Lung Cancer 59: 350-354, 2008.
21. Cristaudo A, Foddis R, Vivaldi A, Guglielmi G, Dipalma N, Filiberti R, Neri M, Ceppi M, Paganuzzi M, Ivaldi GP, Mencoboni M, Canessa PA, Ambrosino N, Chella A, Mutti L and Puntoni R: Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res 13: 5076-5081, 2007.
22. Beyer HL, Geschwindt RD, Glover CL, Tran L, Hellstrom I, Hellstrom KE, Miller MC, Verch T, Allard WJ, Pass HI and Sardesai NY: MESOMARK: A potential test for malignant pleural mesothelioma. Clin Chem 53: 666-672, 2007.
23. Di Serio F, Fontana A, Loizzi M, Capotorto G, Maggiolini P, Mera E, Bisceglia L and Molinini R: Mesothelin family proteins and diagnosis of mesothelioma: Analytical evaluation of an automated immunoassay and preliminary clinical results. Clin Chem Lab Med 45: 634-638, 2007.
24. INAIL. National Register of Mesothelioma. IV report. INAIL edition, Rom 2012.
25. Fazzo L, Minelli G, De Santis M, Bruno C, Zona A, Marinaccio A, Conti S, Pirastu R and Comba P: Mesothelioma mortality surveillance and asbestos exposure tracking in Italy. Ann Ist Super Sanita 48: 300-310, 2012.
26. Creaney J, Yeoman D, Naumoff LK, Hof M, Segal A, Musk AW, De Klerk N, Horick N, Skates SJ and Robinson BW: Soluble mesothelin in effusions: A useful tool for the diagnosis of malignant mesothelioma. Thorax 62: 569-576, 2007.
27. Marinaccio A, Altavista P, Binazzi A, Comba P, Mastrantonio M, Nesti M, Pasetto R, Scarselli A, Uccelli R and Pirastu R: Pleural cancer mortality and compensated cases of asbestosis in Sardinia Region municipalities (1980-2000). Epidemiol Prev 29: 57-62, 2005.